Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.

World J Urol · 2023 · PMC10415491 · PMID 36287244

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Discussion In the present small monocentric real-world study, we observed a clear trend towards a benefit of NHT + ADT compared to Docetaxel + ADT regarding OS, PFS and TTP in our study population.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.